Research Project

WhatsApp Image 2025-01-30 at 20.23.44
Biofilm and Superbugs Research Team

Research Title: Optimization of Polymyxins as an Antibiofilm Agent and Efflux Pump Inhibitor for Controlling Chronic Infections Caused by Carbapenem-Resistant Acinetobacter baumannii (CRAB)

Research Aim:

This research aims to provide new understanding regarding the inhibition of biofilm formation and the mechanism of efflux pump resistance in CRAB, which can support the development of anti-biofilm combination therapy and optimize the use of polymyxins to treat resistant bacterial infections.

Research Object (Type of Material and Research Scope):

  • Type of Material: Acinetobacter baumannii resistant to carbapenems (CRAB).
  • Research Scope: This study will focus on biofilm formation and efflux pump resistance mechanisms in CRAB. It will also investigate the combination of polymyxins with other antibiofilm agents, such as silver nanoparticles or efflux pump inhibitors, to combat difficult-to-treat CRAB infections.

Research Duration:

  • Start: February 2025
  • End: November 2025

Research Location (Lab/Studio/Field):

  • Microbiology Laboratory, Faculty of Medicine, Hasanuddin University, Makassar, Indonesia.
  • Research and Development Laboratory, Department of Microbiology and Infectious Diseases, Erasmus MC, Rotterdam, Netherlands.

Other Involved Institutions (if any, and their contributions):

  • Erasmus MC, Rotterdam, Netherlands:
    • Provides expertise in advanced molecular and microbiological techniques.
    • Supports experiments focusing on biofilm formation and efflux pump mechanisms in carbapenem-resistant Acinetobacter baumannii.

Expected Findings (Explanation of Symptoms, Principles, Methods, Theories, Products, or Engineering Outcomes):

  • Identify biofilm formation mechanisms and efflux pump activity in CRAB.
  • Explore the effectiveness of polymyxin combinations with other antibiofilm agents to address complex CRAB infections.
  • Generate recommendations for more efficient last-line therapies to reduce dependence on expensive new antibiotics.

Fundamental Contribution to Science (Max 50 words, emphasizing the fundamental and original ideas that will support scientific and technological development):

This research provides new insights into biofilm inhibition and efflux pump resistance mechanisms in CRAB. It supports the development of combination antibiofilm therapies and optimizes polymyxin use to treat resistant bacterial infections.

Targeted Scientific Journals (Reputable International, National Accredited, or Non-Accredited Journals and Planned Year of Publication):

  • Antimicrobial Agents and Chemotherapy (Reputable International Journal) or International Journal of Antimicrobial Agents (Reputable International Journal).
  • Planned publication: December 2025.

Additional Expected Outcomes (Intellectual Property, Books, Prototypes, or Other Outputs, and the Planned Year of Completion):

  • A book on the development of combination antibiofilm therapies for CRAB infections.
  • Planned completion year: 2026.
Picture2
Future Research
  1. Development and validation of an ex-vivo skin infection model that mimics the conditions found in humans suffering from XDR and Pandrug-resistant pathogen including an A. baummanii skin infection (AbSi HuMimicon) for screening active antibiotic combinations..
  2. Potential of plant/coral extract as an alternative antibiotic/potentiation agent for XDR or Pandrug-resistant (using AbSi HuMimicon platform)
WhatsApp Image 2025-01-30 at 10.15.12
Detailed Outline
WhatsApp Image 2025-01-30 at 10.15.13
Understanding Biofilm Infections and the Rise of Superbugs: Mechanisms, Implications, and Treatment Strategies

Overview: This research aims to explore the formation and characteristics of biofilms and their role in the emergence of antibiotic-resistant superbugs. Biofilms are communities of microorganisms that adhere to surfaces and are encased in a protective matrix, leading to persistent infections and treatment challenges. Superbugs, or multidrug-resistant bacteria, often exploit biofilm formation to evade conventional therapies. This study will investigate the mechanisms of biofilm formation, their impact on infection severity, and potential therapeutic strategies to combat these infections.

Biofilms are ubiquitous in nature and can form on various surfaces, including medical devices, tissues, and natural environments. In a clinical context, biofilm formation significantly complicates treatment, as bacteria in biofilms exhibit heightened resistance to antibiotics—up to 1,000 times greater than their planktonic counterparts. Superbugs, such as Methicillin-resistant Staphylococcus aureus (MRSA) and Pseudomonas aeruginosa, are often associated with biofilm infections, leading to increased morbidity and healthcare costs. This research aims to address the following questions:

  • What are the key mechanisms underlying biofilm formation and maintenance?
  • How do biofilms contribute to antibiotic resistance in superbugs?
  • What novel treatment strategies can effectively disrupt biofilm formation and enhance antimicrobial efficacy?

Methicillin-resistant Staphylococcus aureus (MRSA), Escherichia coli (especially Extended Spectrum Beta-Lactamase (ESBL) producers), and Carbapenem-resistant Enterobacteriaceae (CRE), are associated with increased morbidity, mortality, and healthcare costs. Timely identification of these pathogens is critical for appropriate antibiotic therapy. MALDI-TOF MS has emerged as a powerful tool for microbial identification due to its speed, accuracy, and cost-effectiveness

 

Objective: The primary aim of this research is to enhance awareness and understanding of biofilm infections and the challenges posed by superbugs among healthcare professionals, patients, and the general public. This will be achieved through the following specific objectives:

  1. Increase Knowledge: Educate stakeholders about the nature of biofilms, their formation, and their role in persistent infections caused by superbugs. This includes understanding the mechanisms that allow biofilm-forming bacteria to resist treatment.
  2. Highlight Clinical Implications: Emphasize the impact of biofilm-associated infections on patient outcomes, healthcare costs, and the challenges in diagnosis and treatment. This includes discussing the importance of early detection and appropriate antimicrobial therapy.
  3. Promote Best Practices: Advocate for best practices in infection prevention and control within healthcare settings to minimize the risk of biofilm-related infections. This includes promoting proper sterilization techniques and responsible antibiotic use.
  4. Encourage Research and Innovation: Foster interest in ongoing research aimed at developing new diagnostic tools and treatment strategies for biofilm infections, including novel antibiotics and alternative therapies.
  5. Engage the Community: Mobilize community efforts to raise awareness about antibiotic resistance and the importance of responsible antibiotic use to prevent the emergence of superbugs.
  6. Provide Resources: Develop educational materials and resources for healthcare providers, patients, and the public to facilitate better understanding and management of biofilm infections and superbugs.